US Advances Development of BioCryst's Potential Ebola Drug

Wednesday, 13 Aug 2014 01:48 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

BioCryst Pharmaceuticals Inc. said the U.S. government exercised options to test the company's antiviral drug in humans and non-primates as a treatment for hemorrhagic fever viruses such as Ebola.

The biotechnology company's shares rose as much as 4.4 percent in morning trade.

BioCryst said it would receive $4.1 million from the National Institute of Allergy and Infectious Diseases to advance development of an intramuscular formulation of its drug, BCX4430.

"BCX4430 appears to be an ideal product candidate as the agency (NIAID) is intent on moving away from its historical 'one bug, one drug' approach towards more broad-based therapeutic agents," Needham & Co. analyst Serge Belanger said in a note.

Companies with potential Ebola therapies have captured the spotlight as developers face mounting pressure to expedite research on new medical interventions to combat the deadly outbreak.

So far, no Ebola drugs or vaccines have entered mid-stage human trials, let alone been approved. The most advanced have been tested only in monkeys and a handful of humans.

The World Health Organization said on Tuesday that people infected in the West African Ebola outbreak could be offered untested drugs, ushering in an opportunity for companies with potential Ebola drugs of their own.

However, some analysts are skeptical of the speed at which these potential Ebola cures will be adopted.

"Given that BCX4430 is a preclinical candidate and has yet to be tested in humans, it's unlikely it will be used during the current Ebola virus outbreak," Belanger added.

Fragile health systems, significant deficits in resources and infrastructure, and the general inexperience in dealing with Ebola outbreaks could act as hurdles to the adoption of potential Ebola therapies, MLV & Co. analyst Vernon Bernardino said.

The NIAID funding is part of the up to $22 million contract awarded to BioCryst by the agency last September.

NIAID is also supporting the development of GlaxoSmithKline Plc and Johnson & Johnson's experimental Ebola vaccines.

Birmingham, Alabama-based BioCryst's stock was up about 2 percent at $13.67 on the Nasdaq on Wednesday.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Smartphone Encryption May Set Up Law Enforcement Fight for Data

Tuesday, 23 Sep 2014 10:24 AM

Smartphone makers Apple and Google are on track for a showdown with the government on new encryption features that makes . . .

Cyber Expert Weisman: Chinese Hacking 'Scares the Hell Out of Me'

Monday, 22 Sep 2014 13:22 PM

Cyber expert Steven J.J. Weisman and Javier Manjarres, managing editor of The Shark Tank Blog, talked to JD Hayworth on  . . .

Gov. Jerry Brown Signs Bills Promoting Electric Car Usage

Monday, 22 Sep 2014 12:10 PM

California Gov. Jerry Brown signed several bills on Sunday intended to boost his state's electric car market, including  . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved